摘要
目的 探讨中晚期卵巢癌患者采用紫杉醇联合洛铂腹腔化疗对临床疗效、免疫功能及生存周期的影响。方法 选取2021年1月至2022年1月山东颐养健康集团淄博医院收治的92例中晚期卵巢癌患者作为研究对象,按随机数字表法分为观察组(n=46)与对照组(n=46)。对照组给予紫杉醇联合洛铂静脉化疗,观察组给予紫杉醇联合洛铂腹腔化疗,比较两组临床疗效、免疫功能、生存周期及不良反应。结果 观察组(54.35%)客观有效率(DCR)较对照组(30.43%)更高(P<0.05);治疗后,两组CD3^(+)、CD4^(+)升高(P<0.05),CD8^(+)降低(P<0.05),与对照组比较,观察组CD3^(+)、CD4^(+)更高(P<0.05),CD8^(+)更低(P<0.05);观察组12个月生存率较对照组更高(P<0.05),总生存期、无进展生存期更长(P<0.05);观察组(47.83%)不良反应发生率较对照组(73.91%)更低(P<0.05)。结论 紫杉醇联合洛铂腹腔化疗应用于中晚期卵巢癌患者治疗中,能够提高临床疗效,改善免疫功能,延长生存周期,降低不良反应发生率。
Objective To explore the effects of paclitaxel combined with intraperitoneal chemotherapy with lobaplatin on clinical efficacy,immune function,and survival cycle in patients with advanced ovarian cancer.Methods Ninety-two patients with advanced ovarian cancer admitted to Zibo Hospital of Shandong Nursing and Health Group from January 2021 to January 2022were selected as the study objects,and were divided into observation group(n=46) and control group(n=46) according to random number table method.The control group was given taxol combined with loplatin intravenous chemotherapy,and the observation group was given paclitaxel combined with loplatin intraperitoneal chemotherapy.The clinical efficacy,immune function,survival cycle and adverse reactions of the two groups were compared.Results The objective effective rate(DCR) of observation group(54.35%) was higher than that of control group(30.43%)(P<0.05).After treatment,CD3^(+) and CD4^(+) increased in both groups(P<0.05),while CD8^(+) decreased(P<0.05).Compared with the control group,CD3^(+) and CD4^(+) were higher in the observation group(P<0.05),and CD8^(+) was lower in the control group(P<0.05).The 12-month survival rate of the observation group was higher than that of the control group(P<0.05),and the overall survival and progression-free survival were longer(P<0.05).The incidence of adverse reactions in observation group(47.83%) was lower than that in control group(73.91%)(P<0.05).Conclusion The application of paclitaxel combined with intraperitoneal chemotherapy with lobaplatin in the treatment of advanced ovarian cancer patients can improve clinical efficacy,improve immune function,prolong survival cycle,and reduce the incidence of adverse reactions.
作者
徐福彦
XU Fu-Yan(Department of Obstetrics and Gynecology,Shandong Health Group Zibo Hospital,Zibo 255120,China)
出处
《中国药物经济学》
2024年第7期78-81,共4页
China Journal of Pharmaceutical Economics
关键词
中晚期卵巢癌
紫杉醇
洛铂
腹腔化疗
免疫功能
生存周期
Mid to late stage ovarian cancer
Paclitaxel
Loplatin
Abdominal chemotherapy
Immune function
Life cycle
